BSX · Healthcare

BOSTON SCIENTIFIC CORP

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-07

• Acquisition / Partnership / DivestitureImportance 40 · Surprise 42
  Boston Scientific secured up to US$455 million from Blackstone Life Sciences to co-fund development of its VITALYST heart pump. The reported funding is up to US$455 million; the digest does not specify a funding…
• Product Pipeline ProgressImportance 40 · Surprise 42
  Boston Scientific secured up to US$455 million from Blackstone Life Sciences to co-fund development of its VITALYST heart pump. The reported funding is directed toward development of the heart-pump product; the digest…

News · 2026-11-06

• Liquidity and Capital PositionImportance 59 · Surprise 42
  S&P Global Ratings revised Boston Scientific’s outlook to negative from stable, citing commercial headwinds and financial leverage expected to remain stretched through 2028. S&P affirmed the company’s 'A-' issuer…
• Acquisition / Partnership / DivestitureImportance 44 · Surprise 42
  Boston Scientific and Blackstone Life Sciences entered a $455 million co-funding collaboration to develop the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System. The miniature heart pump is…
• Guidance / OutlookImportance null · Surprise null
  S&P Global Ratings changed Boston Scientific’s outlook to negative from stable while affirming its ‘A-’ issuer credit and senior unsecured debt ratings. S&P warned that commercial headwinds across core product…

News · 2026-11-05

• Market Demand TrendsImportance 35 · Surprise 48
  The global bioelectronic medicine and neural interface devices market grew from $2.02 billion in 2025 to $2.45 billion in 2026, a reported 21.4% compound annual growth rate. ResearchAndMarkets projects the market will…

News · 2026-11-04

• Guidance / OutlookImportance 53 · Surprise 60
  Management anticipates 2027 will be the low point of Boston Scientific’s current cycle. The company cut its full-year 2026 outlook after third-quarter organic sales growth came in below its prior guidance. Management…
• Acquisition / Partnership / DivestitureImportance 52 · Surprise 42
  Boston Scientific agreed to a co-funding partnership with Blackstone Life Sciences to develop VITALYST, a next-generation heart pump for cardiogenic shock. The report describes the deal as securing $455 million for the…
• Revenue Performance and MixImportance 45 · Surprise 50
  Boston Scientific reported third-quarter 2026 revenue of $5.14 billion, up 1.5% year over year on a reported, operational and organic basis. Organic sales growth was below the company’s prior 3%–5% guidance. An August…
• Supply Chain Cybersecurity RiskImportance 45 · Surprise 50
  An August cybersecurity incident disrupted Boston Scientific’s global network, manufacturing, and shipments for eight business days. The report estimates the disruption reduced third-quarter organic sales growth by…
• Product / Pipeline ProgressImportance 34 · Surprise 42
  Boston Scientific agreed to co-fund development of VITALYST, a next-generation heart pump intended for cardiogenic shock, with Blackstone Life Sciences. The report describes this as the first jointly financed…

News · 2026-11-03

• Guidance / OutlookImportance 31 · Surprise 42
  Third-party reporting says management expects 2027 to be the trough of Boston Scientific’s current cycle. Management is targeting a more meaningful performance improvement for 2028. The report provides no revenue,…

10-Q · 2026-11-02

• Income Tax Rate ChangesImportance 71 · Surprise 82
  The reported tax rate for the first nine months of 2026 was 4.5%, compared with 17.2% in the same 2025 period; the rate from continuing operations was 17.4% versus 18.1%. A $383 million discrete tax benefit in the…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Boston Scientific agreed to acquire 100% of Penumbra for approximately $14.5 billion, valued at $374 per share when announced on January 15, 2026. Penumbra stockholders approved the transaction on May 6, 2026, and the…
• Restructuring and Cost SavingsImportance 58 · Surprise 42
  On July 21, 2026, the Board approved and Boston Scientific committed to a new global restructuring program intended to improve cost efficiency and align resources with strategic priorities. The 2026 Restructuring Plan…
• Stock Repurchase ProgramImportance 57 · Surprise 42
  On February 18, 2026, the board added $4.0 billion to the existing $1.0 billion share-repurchase authorization, bringing the total authorization to $5.0 billion. Under an accelerated share repurchase agreement, Boston…
• Cybersecurity Incident DisruptionImportance 53 · Surprise 68
  Boston Scientific identified a cybersecurity incident in August 2026 that disrupted global operations, including manufacturing and the processing and shipment of customer orders. The company said the incident…
• Revenue Performance and MixImportance 43 · Surprise 32
  Net sales increased 1.5% to $5.138 billion in the third quarter of 2026 and 6.7% to $15.784 billion in the first nine months, with nine-month organic growth of 5.8%. Nine-month Cardiovascular sales grew 7.8% to $10.532…
• Net Income and EPS PerformanceImportance 38 · Surprise 30
  Third-quarter reported net income attributable to Boston Scientific common stockholders declined 22.9% year over year, and diluted EPS fell 20.6% to $0.40. Adjusted net income declined 5.5% to $1.063 billion and…
• Gross Margin DriversImportance 33 · Surprise 32
  Third-quarter gross profit was $3.428 billion, down from $3.542 billion a year earlier, and gross margin declined from 69.9% to 66.7%. The 3.2-percentage-point quarterly margin decline included a 1.7-point adverse…
• Competition and Market ShareImportance 26 · Surprise 24
  Boston Scientific reported increased competition in its Electrophysiology business unit during the third quarter and first nine months of 2026. Competition offset growth in Cardiovascular and contributed to pressure on…
• Products and TechnologyImportance 26 · Surprise 24
  Boston Scientific attributed Cardiovascular growth to its coronary therapies franchise, led by the AGENT Drug-Coated Balloon, and, for the first nine months, to Electrophysiology led by the Farapulse Pulsed Field…
• Operating Cash Flow and CapexImportance 25 · Surprise 32
  Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily because of increased working-capital payments. Investing activities used $2.984 billion,…
• China Pricing PressureImportance 20 · Surprise 24
  Volume-based procurement (VBP) in China contributed to third-quarter Endoscopy sales declines. In Urology, VBP-related underperformance in the stone franchise contributed to declines in both the third quarter and first…
• Liquidity and Capital PositionImportance 13 · Surprise 6
  At September 30, 2026, Boston Scientific held $609 million of unrestricted cash and cash equivalents. It had $1.029 billion outstanding under its commercial-paper program, no borrowings under its $3.0 billion revolving…

News · 2026-11-02

• Acquisition / Partnership / DivestitureImportance 58 · Surprise 42
  Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. VITALYST is a…
• Revenue Performance and MixImportance 52 · Surprise 32
  Boston Scientific reported nine-month 2026 sales of $15.784 billion, up 6.7% year over year, an increase of approximately $994 million from the prior-year period. Third-quarter sales were $5.138 billion, compared with…
• Net Income and EPS PerformanceImportance 47 · Surprise 48
  Boston Scientific’s third-quarter 2026 net income declined to $580 million from $755 million in Q3 2025, a decrease of approximately 23%. A separate Q3 summary reported net income of $582 million, down 22.9%, and…
• Cybersecurity Incident DisruptionImportance 38 · Surprise 42
  A third-party summary of Boston Scientific’s third-quarter filing said an August cybersecurity incident disrupted manufacturing and order fulfillment. The report did not specify which products, facilities, or customer…
• Product Pipeline ProgressImportance 34 · Surprise 42
  Boston Scientific and Blackstone Life Sciences announced a collaboration to co-fund development of Boston Scientific’s VITALYST temporary percutaneous transvalvular circulatory support system. The next-generation…
• Products and TechnologyImportance 31 · Surprise 42
  Boston Scientific reported positive six-month primary endpoint results from the SIMPLAAFY randomized trial of its WATCHMAN FLX Pro left atrial appendage closure device. In patients with non-valvular atrial…

News · 2026-10-30

• Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
  Boston Scientific is reportedly pursuing an acquisition of Penumbra, according to TradingView’s October 30 report. The report says Penumbra’s Q3 2026 results confirmed the pursuit. It provides no transaction value,…
• Guidance / OutlookImportance 20 · Surprise 24
  Oppenheimer downgraded Boston Scientific from Outperform to Perform, citing growth concerns following the company’s third-quarter results. The report says the company is projected to have no growth in 2027, but does…

Earnings call · 2026-10-28

• Cybersecurity Incident DisruptionImportance 57 · Surprise 58
  The cyber incident reduced Q3 organic revenue growth by approximately 300 basis points, or roughly $150 million, and reduced adjusted EPS by $0.07. The eight-business-day disruption prevented manufacturing and product…
• Operating Cash Flow and CapexImportance 51 · Surprise 24
  Q3 free cash flow was $867 million, comprising $1.05 billion of operating cash flow less $180 million of net capital expenditures. Management expects full-year 2026 free cash flow of approximately $3.6 billion,…
• Market Demand TrendsImportance 49 · Surprise 32
  Management described 2026 as a downturn after several years of exceptional growth, with EP and WATCHMAN now weighing on company growth. It said the remaining roughly 75% of the business has historically grown about 6%…
• Guidance / OutlookImportance 47 · Surprise 32
  Boston Scientific expects full-year 2026 reported revenue growth of approximately 4.25%, including an estimated 50-basis-point foreign-exchange tailwind, and operational and organic growth of approximately 3.75%.…
• Restructuring and Cost SavingsImportance 45 · Surprise 42
  Boston Scientific is implementing a company-wide restructuring program covering organizational structure, headcount, discretionary spending, back-office transformation, and supply-chain optimization. Management expects…
• Gross Margin DriversImportance 43 · Surprise 32
  Q3 adjusted gross margin was 68.0%, down 300 basis points year over year, primarily because the cyber-related disruption caused unfavorable manufacturing absorption. Management expects full-year 2026 adjusted gross…
• Acquisition / Partnership / DivestitureImportance 43 · Surprise 42
  Boston Scientific expects to close its acquisition of Penumbra in early 2027, subject to remaining regulatory clearances. Management said Penumbra’s portfolio and strategic fit are expected to strengthen the company’s…
• Competition and Market ShareImportance 43 · Surprise 42
  Management said new technologies and dynamically changing adoption of PFA form factors have eroded Boston Scientific’s formerly strong EP share position, with the cyber incident accelerating some of the shift. It…
• Products and TechnologyImportance 37 · Surprise 40
  Neuromodulation grew 13%, led in pain by Nalu PNS and in brain by the Cartesia X lead and Illumina 3D software; management also cited positive three-month real-world outcomes for Intracept in the IMPROVE study.…
• WATCHMAN Demand SlowdownImportance 37 · Surprise 32
  WATCHMAN sales declined 7% in the U.S. and grew 4% internationally; U.S. concomitant procedures increased approximately 35%, while standalone procedures fell by a high-teens percentage. Management attributed the…
• Operating Income and MarginsImportance 36 · Surprise 32
  Q3 adjusted operating margin was 26.5%, contracting 150 basis points year over year, primarily because the cyber incident pressured gross margin. GAAP operating margin was 16.1% and included an approximately $80…
• Supply Chain And InventoryImportance 32 · Surprise 24
  Management said TCAR supply constraints affected vascular therapies, but expected supply to improve through Q4 and be fully resolved by early 2027. Interventional oncology and embolization growth was partly offset by…
• Revenue Performance and MixImportance 31 · Surprise 32
  Q3 2026 consolidated revenue was $5.14 billion, up 1.5% year over year, below the 3%–5% guidance range. Organic revenue growth was also 1.5%, and management estimated the cyber incident reduced growth by approximately…
• Income Tax Rate ChangesImportance 31 · Surprise 32
  The Q3 2026 adjusted tax rate was 14.3%, higher than expected because of discrete tax items. Under current legislation, Boston Scientific now expects its full-year 2026 adjusted tax rate to be approximately 12%.
• Urology and Endoscopy TrendsImportance 31 · Surprise 32
  Urology declined 3% in Q3, affected by the cyber incident and expanding China pricing pressure; management said recent stone-product approvals and commercial-team stabilization should improve its growth profile during…
• Geographic Revenue PerformanceImportance 25 · Surprise 32
  In Q3 2026, U.S. operational sales were flat year over year, with performance driven by IC, IoE, and neuromodulation. Europe, Middle East, and Africa grew 6% operationally. Asia Pacific declined 1% operationally,…
• Liquidity and Capital PositionImportance 15 · Surprise 6
  As of September 30, 2026, Boston Scientific had $690 million of cash on hand and a gross debt leverage ratio of 1.9x. Management described its capital allocation priorities as strategic tuck-in M&A and opportunistic…
• Product Pipeline ProgressImportance 15 · Surprise 42
  Management said several major platforms have experienced approximately six-month delays, citing the complexity of clinical trials and regulatory processes, and said it is prioritizing high-scale, high-quality launches.…
• China Pricing PressureImportance 15 · Surprise 24
  Management said pricing dynamics in China have become more challenging, with VBP and other pricing effects affecting a number of businesses. It expects growth in the market to moderate to single digits and anticipates…
• Strategic InitiativesImportance 9 · Surprise 42
  Boston Scientific entered an agreement with Blackstone Life Sciences to co-fund development of the Vitalist Circulatory Support System for cardiogenic shock. Funding will reduce R&D expense as related costs are…
• FARAFLEX Trial Readiness and SupplyImportance 9 · Surprise 24
  Management cited FDA IDE negotiations, delays in CMS full approval, and operational challenges completing FARAFLEX cases and expanding study sites as factors affecting the program. It said it had just received CMS…
• Interest Rate EnvironmentImportance 9 · Surprise 24
  Management said interest rates have increased since Boston Scientific announced its Penumbra acquisition in mid-January. Those higher rates are expected to raise incremental financing costs and put additional pressure…
• Mechanical Circulatory Support PositioningImportance 8 · Surprise 24
  Management said evidence from a competitor had raised questions about broad mechanical circulatory support use in high-risk PCI, but it continues to see a role for the therapy and emphasizes better patient selection.…
• TIVUS Trial Enrollment and PositioningImportance 7 · Surprise 24
  Enrollment in the TIVUS renal denervation clinical trial has been slower than management hoped, partly as the Relievant team was transitioned and integrated into Boston Scientific. Management said it remains confident…
• Ultra Product Verification DelayImportance 7 · Surprise 24
  Ultra is a PMA supplement that does not require a clinical study. Management attributed the one-quarter delay to design verification and validation work across the hardware, software, and catheter project. It said the…

8-K · 2026-10-28

• Market Demand TrendsImportance 30 · Surprise 40
  Third-quarter 2026 net sales in the Neuromodulation business grew 13.1% reported and 13.0% operational and organic year over year, exceeding the 10% materiality threshold. The company reported that the growth rates for…
• Geographic Market CommentaryImportance 30 · Surprise 40
  Third-quarter 2026 net sales in Latin America and Canada (LACA) grew 16.0% reported and 10.5% operational year over year. Europe, Middle East and Africa (EMEA) grew 4.4% reported and 6.1% operational, while the U.S.…